Noxopharm Limited

Noxopharm has signed another Material Transfer Agreement (MTA) with an overseas company, demonstrating ongoing interest in its Sofra™ technology platform. CEO Dr Gisela Mautner said: “The signing of another MTA shows that companies continue to be interested in our technology, and their willingness to spend their own resources to evaluate our proprietary assets is a positive sign reflecting the momentum we have built over recent months.” Read more in the latest quarterly here: https://lnkd.in/gkFCuf5e

Dr Olivier Laczka, Noxopharm’s Chief Scientific Officer – Inflammation, has presented to an influential audience at this week’s 20th Annual Meeting of the Oligonucleotide Therapeutics Society. Noxopharm’s versatile Sofra technology platform continues to attract attention as it targets inflammation related to RNA vaccines and therapeutics, as well as autoimmune diseases. Read more about Sofra here: https://lnkd.in/gcVkuSGF

Noxopharm is pleased to announce it has contracted a specialist supplier to manufacture SOF-SKN™ for the upcoming HERACLES clinical trial. SOF-SKN is a novel drug candidate for autoimmune diseases, specifically cutaneous lupus erythematosus (CLE), and the first-in-human trial is planned to start in early 2025. The manufacturing contract involves highly specialised work to produce sufficient quantities of SOF-SKN at rigorous quality standards to support the trial. SOF-SKN contains a proprietary ultra-short oligonucleotide that binds to specific inflammation receptors in the body to reduce inflammation at its source. Read more here: https://lnkd.in/g3zcbhDn

Noxopharm CEO Dr Gisela Mautner will be speaking at next year's ANZ Biologics Festival in Melbourne. Looks like being a great event for the industry, with a wide variety of speakers and topics.

Noxopharm has released its 2024 Annual Report, and it's available on the website here: https://lnkd.in/gBvj8kHq

Noxopharm CEO Dr Gisela Mautner caught up this week with Jenny Ware MP, the Member for Hughes and Co-Chair of the Parliamentary Friends of Autoimmune Diseases. On the agenda were the impact these diseases have on many people in Australia, and the role of industry in developing new treatments. Many thanks to Jenny for her time and her ongoing commitment to public health. 

SOF-SKN contains a proprietary ultra-short oligonucleotide that binds to specific inflammation sensors in the body to reduce inflammation at its source. Watch a video of how it works here: https://lnkd.in/gR796NAD

Noxopharm has completed formulation development for its SOF-SKN™ lupus medication in advance of the upcoming HERACLES clinical trial. The topical formulation has been specifically designed to deliver therapeutic levels of the drug as deep as the dermis – the layer of skin that contains the specific inflammation sensors targeted by SOF-SKN. Read more here:  https://lnkd.in/g3i78xye

LAST CALL: Join Our FREE Webinar Tomorrow on FDA's Platform Technology Draft Guidance! Time is running out to secure your spot for our highly anticipated FREE webinar: "FDA's Platform Technology Draft Guidance: What Does it Mean for mRNA Product Development?" This is your chance to dive deep into the latest insights on the FDA’s draft guidance and how it shapes the future of mRNA technology. Join us tomorrow, Wednesday, September 11th at 12:00 pm ET as we bring together top regulatory experts who will unpack the implications of this guidance and showcase the remarkable agility and potential of mRNA in developing innovative vaccines and therapeutics. This FREE webinar is your chance to gain valuable insights into the evolving landscape of mRNA product development without any financial investment. So, what are you waiting for? Register now to secure your spot: https://lnkd.in/ej2v4gFV

For ausbiz viewers, watch Noxopharm CEO Dr Gisela Mautner discuss the company's brain cancer research announcement here https://lnkd.in/g_JzupE2